Abstract
Background
Previous meta-analysis suggested that transdermal fentanyl was not inferior to sustained-release oral morphine in treating moderate-severe cancer pain with less adverse effects. Now, we updated the data and performed a systematic review.
Methods
Updated cohort studies on transdermal fentanyl and oral morphine in the treatment of cancer pain were searched in electronic databases including CBMdisc, CNKI, VIP, Medline, EMBASE and Cochrane Library. Primary end points assessed by meta-analysis were remission rate of pain and incidence of adverse effects. Quality of life was assessed by systematic review, which was the second end point.
Results
32 cohort studies, which included 2651 patients, were included in present study. The remission rate in transdermal fentanyl group and sustained-release oral morphine group were 86.60% and 88.31% respectively, there was no significant difference [RR = 1.13, 95% CI (0.92, 1.38), P = 0.23]. Compared with oral morphine group, there were less adverse effects in terms of constipation [RR = 0.35, 95% CI (0.27, 0.45), P < 0.00001], nausea/vomiting [RR = 0.57, 95% CI (0.49, 0.67), P < 0.00001], and vertigo/somnolence [RR = 0.59, 95% CI (0.51, 0.68), P < 0.00001] in transdermal fentanyl group. Six of selected trials supported either transdermal fentanyl or sustained-release oral morphine improved QOL of cancer patients and one of them showed more patients got better QOL after sustained-release oral morphine transferred to transdermal fentanyl.
Conclusions
Our study showed again that both transdermal fentanyl and oral morphine had the same efficacy in the treatment of moderate-severe cancer pain in Chinese population, but the former might have less adverse effects and better quality of life.
Similar content being viewed by others
Background
For patients with cancer, up to 70% suffered from pain caused by their disease or its treatment [1]. For patients with advanced cancer, pain was described as moderate-severe in approximately 40%-50% and as very severe in 25%-30% [2]. Because pain was an important symptom and occurred frequently in cancer patients, especially for moderate-severe cancer pain, relief of pain should therefore be seen as part of a comprehensive pattern of cancer care.
Since the 1980s, treatment of cancer pain was based on the WHO analgesic ladder. Strong opioids were classified at the highest step of the analgesic ladder. But studies of cancer pain control consistently revealed that up to half of patients received inadequate analgesia and 30% did not receive appropriate drugs for their pain [1]. In China, sustained-release oral morphine and transdermal fentanyl were strong opioids available for the treatment of moderate-severe cancer pain.
Fentanyl is a lipid soluble synthetic opioid, which can be delivered in a transdermal controlled systemic delivery formulation for up to 72 hours. Transdermal fentanyl was accepted to be an effective drug for treating moderate-severe cancer pain. Because it takes 12-24 hours for serum levels to stabilize after starting the patch or changing the dose, it was less flexible and suitable for patients with unstable pain. However, transdermal fentanyl may reduce the rates of some typical opioid-related adverse effects, particularly constipation [3]. In addition, transdermal fentanyl was conveniently administrated, which simplified the procedure of chronic pain treatment and improved the compliance for using the analgesic.
Three systematic reviews of European and American literatures suggested both transdermal fentanyl and sustained-release oral morphine could effectively control moderate-severe cancer pain, but some adverse effects (mainly constipation) seemed to favor transdermal opiates in the preference of patients with moderate-severe cancer pain [4–6]. Our previous meta-analysis of 12 Chinese literatures also found similar result [14, 17, 14, 17, 14, 17, 32–34]. Especially, one of trials supported more patients got better QOL after sustained-release oral morphine transferred to transdermal fentanyl [34].
Cost effectiveness was not an endpoint in the present systematic review, but it was a valuable index to evaluate a drug for clinical use. 2 out of selected trials reported data about cost effectiveness that transdermal fentanyl had higher expenditure to control certain pain than oral morphine [35, 36]. However, we should keep in mind that cost effectiveness was affected by many factors in fact and only 2 out of 32 trials reported data about cost effectiveness when we concluded cost effectiveness was higher in transdermal fentanyl.
Similar with European and American data [4–6], our data also showed that both transdermal fentanyl and sustained-release oral morphine were effective in treating stable moderate-severe cancer pain in Chinese population with less adverse effects for transdermal fentanyl. However, two differences should be pointed out. First, QOL was only analyzed in our study, and data suggested that transdermal fentanyl potentially improved QOL of cancer pain patients and resulted in better compliance compared with oral morphine. Second, more patients were included in the present systematic review and all patients were Chinese.
To explain the results reasonably, several issues should be considered as follow. First, the data source was extracted from abstracted data and not individual patient data (IPD). In general, an IPD-based meta-analysis would give a more robust estimation for the association; therefore, we should interpret the results with care, especially for a positive result. Clearly, further investigations using IPD should be conducted to examine the main end points. Second, all selected trials were cohort studies, which is not most suitable clinical trial to explore the difference of two drugs. Third, heterogeneity existed among the trials when pooled analysis of adverse effects (constipation and nausea/vomiting), fortunately, the data was not materially changed in sensitivity analysis. Fourth, side effects seemed to be lower in our selected trials compared with clinical practice. We thought that these results might be explained in two aspects of small sample in single trial and better tolerance in Chinese population. At last, transdermal fentanyl takes 12-24 hours for serum levels to stabilize after starting the patch and dose increment was trouble in clinic practice, so it is less flexible and needs to be used with caution in patients with unstable pain.
Conclusions
In summary, the present study supported that transdermal fentanyl and sustained-release oral morphine were effective for maintenance therapy of moderate-severe cancer pain in Chinese population, and the former might have less adverse effects. Our results were similar with European and American data, which might suggest that both of opioids have no race choose. In addition, our data suggested transdermal fentanyl might improve QOL more easily. Well-designed randomised control trials should be further conducted in this area.
Abbreviations
- CBMdisc:
-
Chinese Biomedical Literature Analysis and Retrieval System
- CNKI:
-
China National Knowledge Infrastructure
- VIP:
-
Chongqi VIP Information
- QOL:
-
quality of life
- RR:
-
risk ratio
- SE:
-
standard error
- WHO:
-
World Health Organization
- NCCN:
-
National Comprehensive Cancer Network
- IPD:
-
individual patient data.
References
Brennan F, Carr DB, Cousins M: Pain management: a fundamental human right. Anesth Analg. 2007, 105: 205-221. 10.1213/01.ane.0000268145.52345.55.
Ripamonti C, Dickerson ED: Strategies for the treatment of cancer pain in the new millennium. Drugs. 2001, 61: 955-977. 10.2165/00003495-200161070-00005.
Ahmedzai S, Brooks D: Transdermal fentanyl versus sustained release oral morphine in cancer pain: preference, efficacy and quality of life. J Pain Symptom Manage. 1997, 13: 254-261. 10.1016/S0885-3924(97)00082-1.
Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, Simpson K: Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin. 2004, 20: 1419-1428. 10.1185/030079904X2114.
Tassinari D, Sartori S, Tamburini E, Scarpi E, Raffaeli W, Tombesi P, Maltoni M: Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: A meta-analysis and systematic review of the literature. J Palliat Med. 2008, 11: 492-501. 10.1089/jpm.2007.0200.
Tassinari D, Sartori S, Tamburini E, Scarpi E, Tombesi P, Santelmo C, Maltoni M: Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. J Palliat Care. 2009, 25: 172-180.
Yang Q, Chen DL, Bi ZF, Guo SS, Jiang ZM, **e DR: Fentanyl transdermal or sustained-release oral morphine in the treatment of Chinese with moderate-to-severe cancer pain: a meta-analysis of RCTs. Lin Chuang Zhong Liu Xue Za Zhi. 2008, 13: 109-114.
Cao YK, Zhang Y: Clinical observation of transdermal Fentanyl and Morphine Controlled-release tablets used in patients with cancer pain. Lin Chuang Yan Jiu. 2005, 3: 50-52.
Dong HY, Chen GY, Li XL: Clinical observation on the therapeutic effect of durogesic and MS Contin on 70 cases of advanced cancer pain. Zhongguo Yi Shi Za Zhi. 2006, 8: 1430-1431.
Jiang B, Wang M, Wang YJ: A comparison between transdermal fentanyl and oral morphine in the treatment of cancer pain. Zhongguo Zhong Liu Lin Chuang Yu Kang Fu. 2002, 9: 116-117.
** BW, Zhou CC, Zhang J, Li DR, Lv MJ, Lu B: The clinical use of transdermal fentanyl in treatment of cancer pain of lung cancer. Lin Chuang Fei Ke Za Zhi. 2002, 7: 38-39.
Li R, Zhao GJ, Shen H, Du SJ: Clinical observation of morphine sulfate controlled-release tablets and transdermal fentanyl in the treatment of cancer pain. Zhongguo Zong He Lin Chuang. 2002, 18: 471-472.
Meng LH: Clinical observation of transdermal fentanyl in the treatment of moderate-severe cancer pain. Zhonghua Yi Yao Za Zhi. 2004, 4: 425-426.
Shen J, Du LL, Zhang GQ, Wang P, Yu XL, Zhang Y, Han CS: The efficacy of fentanyl strap** for pain in advanced cancer. Qilu Yi Xue Za Zhi. 2004, 19: 511-512.
Wang X, Tong ZS, Li SF, Shi YH: Clinical evaluation of efficacy and side efects of transdermal fentanyl and sustained release morphine in treatment of moderate-severe chronic cancer-related pain. Tian** Yi Ke Da Xue Xue Bao. 2005, 11: 586-589.
Wu JH, Liu HJ, Wu Y: Efficacy evaluation of transdermal fentanyl in the treatment of advanced cancer pain. Zhongguo Yi Xue Li Lun Yu Shi Jian. 2004, 14: 1132-1133.
Zhang SJ, Liu BR, Qian XP: Comparison of the Clinical Efficacy of transdermal fentanyl and MS Contin in the treatment of moderate-severe cancer pain. Dongnan Da Xue Xue Bao (Yi Xue Ban). 2004, 23: 317-319.
Lei W, Liu XG, Liang J: Clinical observation of transdermal fentanyl in the treatment of 67 cases of cancer pain. Lin Chuang Zhong Liu Xue Za Zhi. 2003, 8: 136-137.
Guo JP: Clinical observation of morphine sulfate controlled -release tablets and transdermal fentanyl in the treatment of 63 cases of cancer pain. Nantong Yi Xue Yuan Xue Bao. 2003, 23: 200-201.
Guo YW, Li Y, Zhang LM: Comparison of transdermal fentanyl and MS Contin in treatment of cancer pain. Yao Wu Yu Lin Chuang. 2006, 3: 71-
Li JB, Lin BJ: Clinical observation of transdermal fentanyl in treatment of advanced cancer pain. Jiangxi Yi Yao. 2008, 43: 569-571.
Qu YH: Comparison of transdermal fentanyl and morphine in treating of cancer pain. **zhou Yi Xue Yuan Xue Bao. 2004, 25: 80-
Wu B, Zhao SF: Efficacy analysis of transdermal fentanyl in treating of primary hepatic cancer pain. Yi Xue Li Lun Yu Shi Jian. 2008, 21: 667-668.
Yang L, Wang YF: Clinical observation of duragesic and controlled-release morphine sulfate in treatment of cancer pain. **an Dai Zhong Liu Yi Xue. 2004, 12: 563-565.
Zhang JW: Efficacy observation of transdermal fentanyl in treating of cancer pain. Lin Chuang Hui Cui. 2004, 19: 101-102.
An HZ: Efficacy comparison of transdermal fentanyl and morphine in treating of cancer pain. Shi Yong Zhen Duan Yu Zhi Liao Za Zhi. 2004, 18: 400-401.
Bai Y: Clinical observation of durogesic in treating of morderate to severe cancer pain. **an Dai Lin Chuang Yi Xue. 2006, 32: 34-35.
** XJ, Ma L, Liu CL: Comparison of the Clinical Efficacy of transdermal fentanyl and MS Contin in the treatment of moderate-severe cancer pain. Zhongguo Zhong Liu Lin Chuang. 2002, 29: 825-826.
Lan HT, Deng CM: Clinical observation of durogesic in treating of 68 cases of cancer pain. **bu Yi Xue. 2005, 17: 150-151.
Li RM, Guo YW, Wu JY: Clinical observation of transdermal fentanyl in treating of cancer pain. Shi Yong Zhong Liu Za Zhi. 2005, 2: 174-
Li ZB, Qiu L, Ma L: Comparison of efficacy of transdermal fentanyl and MS-Contin in treating of cancer pain. Guangdong Yao Xue Yuan Xue Bao. 2003, 19: 89-90. 10.3736/jcim20030204.
Lian ZP, Hou EC, Lu YX, Qin B: Efficacy of Durogesic in the treatment of cancer pain. **an Dai Zhong Liu Yi Xue. 2006, 14: 491-492.
Liu XF, Han YG, Guo LG: Clinical observation of durogesic in treating of advanced cancer pain. Zhonghua **an Dai Nei Ke Xue Za Zhi. 2006, 3: 773-
Pang DM, Deng YM: Comparison of transdermal fentanyl and sustained-release oral morphine on cancer pain. Shi Yong Zhong Liu Xue Za Zhi. 2001, 15: 311-313.
Tang CR, Li WF: Medicine economics analysis of durogesic and MS Contin in the treatment of advanced cancer pain. Zhong Liu Fang Zhi Za Zhi. 2005, 12: 479-480.
Wang GS, Sun JL, Ren XJ, **ng JJ, Yan L: A Comparison on the Efect and Cost Between Transdermal Fentanyl and Sustained Release Morphine in the Treatment for Moderate to Severe Cancer Pain. Zhongguo Zhong Liu. 2004, 13: 451-453.
Wang QC, Chu HT, Wang Q, Wei GM: Clinical observation of durogesic in treating of advanced cancer pain. Zhongguo Wu Zhen Xue Za Zhi. 2006, 6: 3730-3731.
Yi JQ, Cai YY, Li YQ, Li D: Clinical observation of morphine sulfate controlled-release tablets and transdermal fentanyl in the treatment of advanced cancer pain. **an Dai Lin Chuang Yi Xue Sheng Wu Gong Cheng Xue Za Zhi. 2003, 9: 332-333.
Zhou ZQ, Xu RD, Li WK, Zhuang WX, Shao PJ, Luo PF: A randomised control trial of transdermal fentanyl in treating of postoperative pain of chemoembolization of primary hepatic cancer. Nanfang Yi Ke Da Xue Xue Bao. 2006, 26: 1826-1827.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000, 283: 2008-2012. 10.1001/jama.283.15.2008.
Loosemore M, Knowles CH, Whyte GP: Amateur boxing and risk of chronic traumatic brain injury: systematic review of observational studies. BMJ. 2007, 335: 809-10.1136/bmj.39342.690220.55.
Staats PS, Markowitz J, Schein J: Incidence of constipation associated with long-acting opioid therapy: a comparative study. South Med J. 2004, 97: 129-134. 10.1097/01.SMJ.0000109215.54052.D8.
Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R: Quality of life and cancer pain: Satisfaction and side effects with trasndermal fentanyl versus oral morphine. J Clin Oncol. 1998, 16: 1588-1593.
Yu SY, Sun Y, Wu YL, Qin SK, **e GR, Liu SJ, Sui GJ, Zhang HC: Transdermal fentanyl for the management of cancer pain: a survey of 4492 patients. Zhonghua Zhong Liu Za Zhi. 2005, 27: 369-372.
Author information
Authors and Affiliations
Corresponding author
Additional information
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
DRX and QY contributed to the conception and design of the study; QY, DRX, and ZMJ contributed to collection and assembly of data; DRX, QY, ZMJ, WM, YDZ, ZFB, and DLC contributed to data analysis and interpretation; QY and DRX contributed to manuscript writing. All authors have read and approved the final manuscript.
Qiong Yang, De-Rong **e contributed equally to this work.
Electronic supplementary material
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
Rights and permissions
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Yang, Q., **e, DR., Jiang, ZM. et al. Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis. J Exp Clin Cancer Res 29, 67 (2010). https://doi.org/10.1186/1756-9966-29-67
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/1756-9966-29-67